Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
Treatment of preeclampsia and eclampsia,Treatment of hypomagnesemia,Prevention of seizures in severe preeclampsia,Management of ventricular arrhythmias (torsades de pointes),Acute nephritis in children (off-label),Cerebral edema (off-label)
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Magnesium is not metabolized; it is primarily excreted unchanged by the kidneys via glomerular filtration and tubular reabsorption. Elimination half-life is approximately 4-6 hours in normal renal function.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
Approximately 25-30% bound to albumin.
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
0.2-0.3 L/kg; distributes primarily in extracellular fluid.
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
IV: 100%. Not administered orally for systemic effect due to poor GI absorption (<30%).
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
GFR 30-50 m L/min: reduce dose by 50% and monitor serum magnesium; GFR <30 m L/min: contraindicated or use extreme caution with dose reduction to 25% of normal and frequent monitoring.
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
Child-Pugh A (mild): no specific adjustment; Child-Pugh B (moderate): use with caution, consider dose reduction; Child-Pugh C (severe): avoid use or reduce dose by 50% with close monitoring of magnesium levels and renal function.
No dosage adjustment required for hepatic impairment.
Loading dose: 20-40 mg/kg intravenously over 1-2 hours; maintenance: 10-20 mg/kg IV every 4-6 hours as needed; maximum infusion rate 150 mg/min; monitor serum magnesium during therapy.
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Reduce initial dose by 25-50% due to age-related decline in renal function; monitor serum magnesium and renal function closely; adjust dose based on GFR and clinical response.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
WARNING: Do not administer undiluted intravenously. Continuous monitoring of serum magnesium levels, respiratory rate, deep tendon reflexes, and urine output is required. Hazardous infusion rates may cause respiratory arrest, cardiac arrest, or death.
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
May cause respiratory depression or arrest if given too rapidly or in excessive doses.,Use with caution in patients with renal impairment due to risk of accumulation and toxicity.,Administer IV with caution in patients receiving digitalis glycosides; may cause heart block.,Monitor deep tendon reflexes, respiratory rate, and urine output during infusion.,Avoid concurrent use of neuromuscular blocking agents; may potentiate blockade.,Use with caution in patients with myasthenia gravis or other neuromuscular disorders.,Risk of hypotension, flushing, and bradycardia with rapid IV administration.
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Hypersensitivity to magnesium sulfate or any component of the formulation,Myocardial damage or heart block (unless used for torsades de pointes),Severe renal impairment (anuria or oliguria) without dialysis,Comatose patients (unless for seizure control),Absence of deep tendon reflexes (sign of hypermagnesemia)
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
Avoid high-calcium or high-phosphate foods that may interfere with magnesium absorption. Limit alcohol and caffeine. No specific dietary restrictions beyond general healthy diet.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
Magnesium sulfate crosses the placenta and is not associated with major teratogenic effects when used for standard obstetric indications. Prolonged exposure (e.g., >5-7 days) in the second/third trimester may cause fetal hypocalcemia, skeletal abnormalities, or neonatal hypotonia. Continuous infusion near delivery may lead to neonatal respiratory depression and flaccidity.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
Magnesium sulfate is excreted into breast milk in low amounts; M/P ratio approximately 0.2-0.3. Usually compatible with breastfeeding but monitor infant for hypotonia, lethargy, or feeding difficulties if high maternal doses are used long-term.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
Pregnancy may increase renal clearance and volume of distribution, potentially requiring higher loading or maintenance doses to achieve therapeutic levels for seizure prophylaxis/prevention. However, standard dosing protocols (e.g., 4-6 g loading, 1-2 g/h maintenance) are typically effective; adjust based on serum magnesium monitoring and renal function.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
Monitor serum magnesium levels closely, especially in renal impairment. Infusion site reactions (phlebitis) may occur; use central line for prolonged therapy. Calcium gluconate should be available as antidote for magnesium toxicity. Assess deep tendon reflexes before and during infusion; loss of patellar reflex indicates impending toxicity. Correct hypokalemia and hypocalcemia concomitantly to enhance magnesium retention.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
Report any flushing, sweating, or feeling of warmth during infusion.,Do not stop the medication abruptly; dose tapering may be needed.,Inform your doctor if you have kidney disease or are taking diuretics.,Avoid alcohol and caffeine, which can worsen electrolyte imbalances.,Stay hydrated but follow fluid restrictions if advised by your doctor.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Felbamate, an antiepileptic drug, potentiates the central nervous system (CNS) depressant effects of magnesium sulfate, a tocolytic and anticonvulsant agent. This additive pharmacodynamic interaction can lead to excessive sedation, respiratory depression, and impaired motor coordination. Clinically, concurrent use may exacerbate hypotonia, hyporeflexia, and somnolence, particularly in patients with renal impairment or those receiving high doses."
"Coadministration of Clevidipine, a dihydropyridine calcium channel blocker, and Magnesium sulfate, which acts as a physiological calcium antagonist, potentiates the hypotensive and negative inotropic effects due to additive inhibition of calcium influx into cardiac and vascular smooth muscle cells. This can lead to exaggerated reductions in blood pressure, bradycardia, and impaired cardiac contractility, particularly in patients with pre-existing cardiovascular compromise. Severe hypotension and heart block have been reported, especially during intravenous administration of both agents."
"The combination of nicardipine, a calcium channel blocker, and magnesium sulfate, a calcium antagonist, synergistically reduces vascular smooth muscle contractility and myocardial conduction. This additive pharmacodynamic effect can lead to profound hypotension, bradycardia, and impaired cardiac contractility, particularly in patients with pre-existing cardiovascular compromise. Clinically, patients may experience symptomatic hypotension, dizziness, or syncope, and in severe cases, cardiovascular collapse may occur."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER is a Electrolyte that works by Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER is: 1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Magnesium sulfate crosses the placenta and is not associated with major teratogenic effects when used for standard obstetric indications. Prolonged exposure (e.g., >5-7 days) in th. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.